Key Points
- John Griffiths, Newport East MS, wrote to the Welsh Government on 27 January 2026, arguing Wales lags internationally in newborn screening, testing only for nine conditions versus 16 in France, 23 in Germany, and 26 in Sweden.
- The letter urges ministers to explore expanding screening for more diseases, highlighting delays in Spinal Muscular Atrophy (SMA) screening and risks of babies/families falling behind the UK without in-service evaluation participation.
- Griffiths supports local families with rare-condition children via casework, citing concerns from discussions on access to trials, care standards, health professional training, and screening gaps.
- On Facebook, Griffiths stated: “Early diagnosis can transform lives and save significant costs for the NHS. It’s vital that Wales keeps pace with international standards and explores opportunities to expand newborn screening.”
- The South Wales Argus contacted Griffiths, who responded: “For the last three years I have been supporting local families who have had children born with a rare condition through my constituency casework… My letter to Welsh Government is part of the ongoing campaign to ensure individuals, who have a rare disease and their loved ones receive the support they need.”
Newport (The Wales Times) February 9, 2026 – Newport East MS John Griffiths has written to the Welsh Government claiming newborn screening in Wales falls below international standards, urging expansion beyond the current nine conditions amid delays in Spinal Muscular Atrophy testing.
What Has John Griffiths Said About Newborn Screening in Wales?
John Griffiths, Newport East MS, argues in a 27 January 2026 letter to the Welsh Government that “Wales and the UK are lagging internationally in the protection of newborns,” as reported by the South Wales Argus. He notes babies are screened for only nine conditions, while other western nations test for more, and urges ministers to “consider new opportunities” and “understand what options exist to ensure that babies in Wales can be screened for more diseases and conditions than at present.”
The letter highlights delays in introducing Spinal Muscular Atrophy (SMA) screening, warning: “without participation in the in-service evaluation, babies and families in Wales will continue to be left behind the rest of the UK.”
Why Does John Griffiths Claim Wales Lags in Newborn Screening?
Griffiths’ letter, covered by the South Wales Argus, compares Wales unfavourably: “For most western nations, there is a far more extensive list of diseases screened for newborn babies. France screens for 16 diseases, Germany 23, and Sweden 26.” He positions this as Wales falling “below par,” based on constituency casework with rare-condition families over three years.
Griffiths told the South Wales Argus: “Different issues have stemmed from this, such as access to clinical trials, standards of care and the training of health professionals. In our most recent conversations, we spoke about the state of play in relation to newborn screening, and it was concerning to hear how far Wales, and the rest of the UK was behind other countries.”
When Was John Griffiths’ Letter Sent and What Was His Follow-Up?
The letter was sent on 27 January 2026, per South Wales Argus reporting. Griffiths followed up on Facebook: “Early diagnosis can transform lives and save significant costs for the NHS. It’s vital that Wales keeps pace with international standards and explores opportunities to expand newborn screening.”
To the South Wales Argus, he elaborated: “For the last three years I have been supporting local families who have had children born with a rare condition through my constituency casework… My letter to Welsh Government is part of the ongoing campaign to ensure individuals, who have a rare disease and their loved ones receive the support they need.”
What Is Spinal Muscular Atrophy (SMA) Screening Delay in Wales?
Griffiths’ letter warns of delays in SMA screening introduction, stating “without participation in the in-service evaluation, babies and families in Wales will continue to be left behind the rest of the UK,” as detailed by the South Wales Argus. This rare genetic disease affects muscle strength and movement, with early detection enabling timely treatment.
The South Wales Argus frames this as part of broader screening shortcomings.
How Many Conditions Are Currently Screened for in Wales?
Wales screens newborns for nine conditions, according to Griffiths’ letter cited in the South Wales Argus. This is fewer than international peers like France (16), Germany (23), and Sweden (26), prompting his call for expansion.
The letter claims this limited scope leaves Wales “lagging internationally.”
What Casework Experience Informed John Griffiths’ Campaign?
Griffiths has supported local families with rare-condition newborns for three years via constituency casework, the South Wales Argus reports. Issues include clinical trial access, care standards, health professional training, and screening gaps, raised in recent family discussions.
He described this to the South Wales Argus as driving his letter and “ongoing campaign.”
What Benefits Does Griffiths Highlight for Expanded Screening?
On Facebook, Griffiths stated to the South Wales Argus: “Early diagnosis can transform lives and save significant costs for the NHS.” He argues expansion ensures Wales matches international standards, preventing families from being “left behind.”
His letter seeks options for more comprehensive disease detection.
Has the Welsh Government Responded to Griffiths’ Letter?
As of the South Wales Argus report, no Welsh Government response appears. The article notes Griffiths contacted them on 27 January 2026, with his public statements amplifying the call.
Coverage focuses on his arguments without ministerial rebuttal.
How Does Wales Compare to Other Western Countries in Screening?
Griffiths’ letter, per South Wales Argus: France screens for 16 diseases, Germany 23, Sweden 26—far exceeding Wales’ nine. This international lag, plus UK-wide issues, underpins his push for improvement.
Specific conditions beyond the nine remain unspecified in reports.
What Is John Griffiths’ Role and Background on This Issue?
John Griffiths is Newport East MS, advocating via letter and casework. The South Wales Argus quotes his three-year support for affected families, tying personal stories to policy critique.
His Facebook post reinforces NHS cost savings from early diagnosis.
Why Focus on Rare Diseases in Newborn Screening?
Griffiths links screening to rare disease support, per South Wales Argus interviews. Casework revealed disparities in trials, care, training—exacerbated by limited screening, leaving Welsh babies vulnerable compared to peers.
His campaign holistically addresses family needs.
What Other Newport News Complements This Story?
South Wales Argus links related local coverage: a thug kicking a pregnant ex-girlfriend, snooker legend John Virgo’s death aged 79, and a main Newport road closure disrupting services—contextualising Griffiths’ health advocacy amid community concerns.
These highlight broader Newport vulnerabilities.
Could Expanded Screening Save NHS Costs in Wales?
Griffiths asserts on Facebook, via South Wales Argus: “Early diagnosis can transform lives and save significant costs for the NHS.” Proactive screening prevents advanced disease management expenses.
His letter positions this as economically vital.
What Is the Current State of UK Newborn Screening?
Griffiths claims the UK, including Wales, lags internationally, screening fewer conditions than western norms. South Wales Argus reports his concerns from family talks, without UK-wide data beyond comparisons.
SMA evaluation participation is urged to align Wales.
How Has John Griffiths Engaged Publicly on This?
Beyond the letter, Griffiths posted on Facebook, quoted by South Wales Argus, and responded to their queries. This multi-channel approach amplifies his campaign for screening parity.
Constituency roots personalise the advocacy.
What Next Steps Does Griffiths Propose?
The letter urges ministers to “consider new opportunities” and detail expansion options, per South Wales Argus. SMA evaluation participation avoids UK lag; his campaign continues supporting rare disease families.
No timeline for government reply noted.
John Griffiths’ intervention spotlights a critical health equity gap, with Wales’ nine-condition newborn screening paling against global leaders. South Wales Argus coverage reveals his evidence-based push—international comparisons, SMA delays, NHS savings—rooted in three years’ casework. Families’ stories of trial access woes and care shortfalls humanise the policy critique, urging Welsh ministers to act. Early diagnosis promise transforms lives, averting rare disease tragedies proactively. Amid Newport’s local headlines—from violence to closures—this underscores preventable vulnerabilities. Griffiths’ campaign, blending letters, Facebook, and interviews, pressures for alignment with France, Germany, Sweden. Outcomes could expand screening, bolstering Welsh NHS efficiency and family support. As devolved health evolves, such MS advocacy ensures infant protections keep pace internationally.
